Abstract:Recently, various bla(KPC-2) variants resistant to ceftazidime-avibactam have begun to emerge in clinical settings, but it is unclear which testing method is most appropriate for detecting these variants. Strains were subjected to antimicrobial susceptibility testing using the broth microdilution method. Four carbapenemase detection methods, modified carbapenem inactivation method (mCIM) and EDTA carbapenem inactivation method (eCIM), APB/EDTA (carbapenemase inhibitor APB [3-aminophenylboronic acid] and EDTA enhancement method), NG-test Carba 5, and GeneXpert Carba-R were used to try to detect KPC-2 variants in 19 Klebsiella pneumoniae isolates. Among those bla(KPC-2) variants, bla(KPC-33)-, bla(KPC-35)-, bla(KPC-71)-, bla(KPC-76)-, bla(KPC-78)-, and bla(KPC-79)-positive isolates accounted for 26.3% (5/19), 15.8% (3/19), 5.3% (1/19), % 42.1% (8/19), 5.3% (1/19), and 5.3% (1/19), respectively. All 19 K. pneumoniae carrying bla(KPC-2) variants showed resistance to ceftazidime-avibactam (MICs:16 to >64 mg/L), and 14 strains were susceptible to imipenem (MICs: 0.25 to 1 mg/ L). None of the bla(KPC-2) variants could be detected using either the mCIM or the APB/EDTA method, while five strains carrying bla(KPC-2) variants (bla(KPC-35), bla(KPC-78), and bla(KPC-79)) tested KPC positive when using NG-test Carba 5. However, GeneXpert Carba-R was able to detect bla(KPC-2) variants (harboring bla(KPC-33), bla(KPC-35), bla(KPC-71), bla(KPC-76), bla(KPC-78), and bla(KPC-79)) carried by all 19 K. pneumoniae. The emergence of new KPC variants poses an increased challenge for carbapenemase detection methods, and laboratories should use the appropriate assays to accurately detect these variants. IMPORTANCE Carbapenemase detection is essential for the appropriate treatment of CRE infections. Several clinical laboratories have begun using relevant carbapenemase assays such as mCIM and eCIM, the APB/EDTA method, NG-test Carba 5, and GeneXpert Carba-R to detect carbapenemases. Nevertheless, some of these methods may have limitations for detecting bla(KPC-2) variants. Additionally, there has been little relevant research on evaluate the differences between these standard methods for detecting bla(KPC-2) variants. Therefore, we investigated the reliability of these classic methods for assessing 19 K. pneumoniae with bla(KPC-2) variants. Our results showed that none of the bla(KPC-2) variants could be detected using either the mCIM or APB/EDTA method, while five strains (harboring bla(KPC-35), bla(KPC-78),and bla(KPC-79)) tested KPC positive when using NG-test Carba 5. GeneXpert Carba-R could detect six bla(KPC-2) variants carried by all 19 K. pneumoniae. This study may be valuable for clinical laboratories in their efforts to test for various bla(KPC-2) variants.

Evaluation on the Accuracy of VITEK 2 Compact for the Susceptibility of Carbapenem-Resistant Klebsiella Peumoniae to Amikacin

Veracity of VITEK-2 Compact in Detection of Drug Susceptibility of Acinetobacter Baumannii to Amikacin

Evaluation of different tigecycline susceptibility testing methods for Acinetobacter baumannii

Evalution of Vitek 1,vitek 2 and BD Phoenix System for Detection of Extended-Spectrum Beta-Lactamases

Detection of extended-spectrum-β-lactamase-producing strains with VITEK2-compact ESBLs test

Efficacy of synergistic antibiotic combinations against KPC-2 carbapenemase producing Klebsiella pneumoniae strains

Accuracy of in Vitro Susceptibility Tests for Carbapenemase-Producing Gram-negative Bacteria

Discrepant Susceptibility to Gentamicin Despite Amikacin Resistance in Klebsiella Pneumoniae by VITEK 2 Represents False Susceptibility Associated with the Arma 16S Rrna Methylase Gene.

Performance of VITEK 2, E-test, Kirby–Bauer Disk Diffusion, and Modified Kirby–Bauer Disk Diffusion Compared to Reference Broth Microdilution for Testing Tigecycline Susceptibility of Carbapenem-Resistant K. Pneumoniae and A. Baumannii in a Multicenter Study in China

Carbapenem resistance of KPC-possessing Enterobacteriaceae

The Evaluation of Four in Vitro Susceptibility Testing Methods for Colistin on Carbapenenm-Resistant Acinetobacter Baumannii

Detection of Β-Lactamases and Genetyping in Carbapenem-Resistant Klebsiella Pneumoniae

Colistin, Meropenem–Vaborbactam, Imipenem–Relebactam, and Eravacycline Testing in Carbapenem-Resistant Gram-Negative Rods: A Comparative Evaluation of Broth Microdilution, Gradient Test, and VITEK 2

Methodology Establishment and Application of VITEK Mass Spectrometry to Detect Carbapenemase-Producing Klebsiella pneumoniae

Comparative Evaluation of Colistin-Susceptibility Testing in Carbapenem-Resistant Klebsiella pneumoniae Using VITEK, Colistin Broth Disc Elution, and Colistin Broth Microdilution

Comparison of Four Carbapenemase Detection Methods for <i>bla</i><sub>KPC-2</sub> Variants

Evaluation of the Vitek 2 system for antifungal susceptibility testing of Candida auris using a representative international panel of clinical isolates: overestimation of amphotericin B resistance and underestimation of fluconazole resistance

Analysis of the Clinical Effect of Combined Drug Susceptibility to Guide Medication for Carbapenem-Resistant Klebsiella Pneumoniae Patients Based on the Kirby-Bauer Disk Diffusion Method

Verification of Ceftazidime-Avibactam and Ceftolozane-Tazobactam Susceptibility Testing Methods Against Carbapenem-Resistant Enterobacteriaceae and Pseudomonas Aeruginosa

Comparative Evaluation of Seven Tigecycline Susceptibility Testing Methods for Carbapenem-Resistant Enterobacteriaceae

Aminoglycoside Resistance Genes in Carbapenem-Resistant Klebsiella Pneumoniae